$9.1+ Billion Antacids Market Poised for Steady Growth: Key Trends and Projections to 2032

PORTLAND, OREGON, UNITED STATES, July 17, 2024 /EINPresswire.com/ -- 𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠: https://www.alliedmarketresearch.com/purchase-enquiry/A10281

Antacids Market Research, 2032

The global antacids market is projected to witness steady growth from $6.7 billion in 2022 to $9.1 billion by 2032, driven by various market dynamics and emerging trends.

Key Market Insights
• Market Size and Growth:
• 2022 Market Value: $6.7 billion
• Projected 2032 Market Value: $9.1 billion
• CAGR: 3.1% from 2023 to 2032
• Antacid Functionality:
• Neutralizes stomach acid.
• Contains active ingredients like aluminum, calcium, magnesium, or sodium bicarbonate.
• Treats symptoms such as acid reflux, heartburn, and indigestion.

Market Dynamics
• Drivers:
• Increasing prevalence of gastroesophageal reflux disease (GERD).
• Rising awareness about digestive health.
• Unhealthy eating habits and sedentary lifestyles.
• Accessibility of over-the-counter (OTC) antacids.
• Restraints:
• Emergence of more effective treatments such as proton pump inhibitors (PPIs) and H2 receptor antagonists.
• Opportunities:
• Lifestyle changes leading to increased demand for antacids.
• COVID-19 pandemic impact with increased gastrointestinal symptoms.

Segmental Overview
• By Mechanism of Action:
• Non-Systemic Antacids: Largest market share in 2022; fastest growth projected.
• Systemic Antacids: Lesser market share due to consumer preference for non-systemic options.
• By Formulation Type:
• Tablets: Dominated market in 2022; popular for convenience and variety.
• Liquids: Fastest growing segment; preferred for ease of use and palatability.
• By Distribution Channel:
• Drug Stores & Retail Pharmacies: Dominated market due to convenience.
• Online Providers: Fastest growing segment; driven by e-commerce popularity.

Regional Analysis
• North America:
• Largest market share in 2022.
• Growth driven by well-developed healthcare infrastructure and high prevalence of gastrointestinal diseases.
• Asia-Pacific:
• Highest growth rate projected.
• Driven by increasing healthcare expenditure and growing awareness about heartburn and gastrointestinal issues.

Competitive Landscape
• Major Players:
• Abbott Laboratories
• Alkem Laboratories Ltd.
• Cipla Ltd.
• Bayer AG
• Haleon Plc
• Infirst Healthcare Inc.
• Pfizer Inc.
• Prestige Consumer Healthcare Inc.
• Reckitt Benckiser Group PLC
• WellSpring Pharmaceutical Corporation
• Other Important Players:
• Major Pharmaceuticals
• Topco Associates, LLC

𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠: https://www.alliedmarketresearch.com/purchase-enquiry/A10281

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X